Published in
American Medical Association, JAMA Oncology, 8(6), p. 1241, 2020
DOI: 10.1001/jamaoncol.2020.2091
Links
Tools
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors
Journal article published in 2020 by
Heikki Joensuu,
Mikael Eriksson,
Kirsten Sundby Hall,
Annette Reichardt,
Barbara Hermes,
Jochen Schütte,
Silke Cameron,
Peter Hohenberger,
Philipp J. Jost,
Salah-Eddin Al-Batran,
Lars H. Lindner,
Sebastian Bauer 
,
Eva Wardelmann,
Bengt Nilsson,
Raija Kallio
and other authors.
,
Eva Wardelmann,
Bengt Nilsson,
Raija Kallio
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Postprint:
archiving forbidden
Published version:
archiving forbidden
Data provided by 